Ventana Medical Systems, Inc.

Genentech, Inc.

National Cancer Center

Nihon University School of Medicine

Hiro Nitta

Michael S Barnes

Thomas M Grogan

Christopher Bieniarz

Atsushi Ochiai

Esteban Roberts

Brian Daniel Kelly

Takeshi Kuwata

Shalini Singh

Crystal Schemp

Wenjun Zhang

Shinobu Masuda

Adrian E Murillo

Stacey Stanislaw

Nelson Alexander

Penny Towne

Fabien Gaire

Alisa Tubbs

June F Clements

Eslie Dennis

Bharathi Vennapusa

Tom Grogan

Masafumi Kurosumi

Thomas Grogan

Mike Farrell

Michael Barnes

Amy A Lo

Mary T Padilla

Edmundo David Del Valle

Donald G Munroe

Akio Kaito

Leigh A Henricksen

Sasagu Kurozumi

James Ranger-Moore

Disclosed herein are methods for identifying a subject as having NSCLC that is predicted or is likely to respond to treatment with an ALK inhibitor, for example crizotinib. The methods include identifying a sample including NSCLC tumor cells as ALK-positive or ALK-negative using immunohistochemistry (IHC) and scoring methods disclosed herein. A subject is identified as having NSCLC likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-positive and is identified as having NSCLC not likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-negative. According to certain embodiments of the methods, subjects predicted to respond to an ALK inhibitor may then be treated with an ALK inhibitor such as crizotinib.

Method of identifying treatment responsive non-small cell lung cancer using anaplastic lymphoma kinase (ALK) as a marker

Disclosed herein are methods for identifying a subject as having NSCLC that is predicted or is likely to respond to treatment with an ALK inhibitor, for example crizotinib. The methods include identifying a sample including NSCLC tumor cells as ALK-positive or ALK-negative using immunohistochemistry (IBC) and scoring methods disclosed herein. A subject is identified as having NSCLC likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-positive and is identified as having NSCLC not likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-negative. According to certain embodiments of the methods, subjects predicted to respond to an ALK inhibitor may then be treated with an ALK inhibitor such as crizotinib.

The present disclosure relates to systems and methods for analyzing chromosomal translocations, and in particular to analysis of chromosomal translocation by in situ hybridization.

Method of analyzing chromosomal inversions

Embodiments of substrates and processes for chromogenic detection, and in particular pyrazolyl dihydrogen phosphate compounds, are disclosed.

Substrates for chromogenic detection and methods of use in detection assays and kits

Growing community of inventors

Tucson, AZ, United States of America

Hiro Nitta